Quadriga BioSciences

Quadriga BioSciences is a private, preclinical-stage biotech advancing a novel oncology therapeutic platform. Its core technology leverages the L-type Amino Acid Transporter 1 (LAT1) to selectively deliver cytotoxic payloads into rapidly proliferating cancer cells and across the blood-brain barrier, addressing a key challenge in treating brain cancers and other solid tumors. The company is singularly focused on developing its lead candidate, QBS72S, a DNA interstrand cross-linking agent. Quadriga appears to be in a capital-efficient, asset-centric development phase, seeking partnerships to advance its program.

A 'Trojan Horse' platform designing small molecule prodrugs that mimic aromatic amino acids to be actively transported into cancer cells and across the blood-brain barrier via the L-type Amino Acid Transporter 1 (LAT1). Once inside cells, the payload (e.g., a DNA cross-linker) is activated to kill the cancer cell.

The field of BBB-penetrant therapies is competitive, involving various modalities (biologics, nanoparticles, other transporter systems). Several academic and industry groups are also investigating LAT1 as a drug delivery target, though QBS72S aims to be a first-in-class chemotherapeutic using this approach.